2023.09.15
Cure Genetics is delighted to announce that Dr. Li Ren has joined the company recently, taking on the role of Chief Technology
Officer in Cell Therapy.
Dr. Ren is a seasoned expert in cell therapy, boasting over 20 years of experience developing and advancing cell therapy drug candidates from pre-clinical to commercial licensure across US, EU, and Japan. Dr. Ren has led the process and analytical development of multiple allogeneic & autologous cell therapy products over her career, including CAR T cells, TCR cells, NK cells, CAR-NK cells and mesenchymal-like stem cells. Over the course of her career, Dr. Ren has supported multiple IND submissions for cell therapy pipeline products to enable clinical trials and designed and led process & analytical validation programs in support of commercial registration filing.
Before her tenure at Cure Genetics, Dr. Ren served as the Vice President of Technical Operations at Chimeric Therapeutics, overseeing the Process Development, Analytical Development, and Manufacturing of its development pipeline. Before Chimeric, Dr. Ren held the position of Director at Bristol-Myers Squibb(BMS) where she was responsible for the technology transfers of Juno’s cell therapy pipeline products to BMS GMP manufacturing facilities. Earlier in her career, Dr. Ren held various leadership roles at Celgene Corporation and Celgene Cellular Therapeutics, where she led the CMC development of multiple allogeneic and autologous cell therapy products. Dr. Ren earned her Ph.D. from Ocean University of China.
Dr. Ren stated, " I am looking forward to joining in Cure Genetics. The company stands out with its distinct advantage and vast commercial potential in the cell therapy pipeline layout. I anticipate working closely with the team to advance the development and application of cell therapy products."
"We are thrilled to welcome Dr. Ren to Cure Genetics," said Dr. Yuanyuan Xu, Chairman and CEO of Cure Genetics. "Her profound experience in cell therapy product development, coupled with her expertise in global IND fillings and commercial registrations, will significantly enhance the rapid development and commercialization of our cell therapy products. I believe her addition will accelerate the realization of our strategic goals and bolster our vision for internationalization."
Cure Genetics, established in Suzhou in 2016, is a clinical-stage company dedicated to developing cell and gene therapies for solid tumors and common genetic diseases. Through our innovative technology platforms, including the Universal CAR-NKT platform AIMS CAR-NKT and our unique AAV platform VELPTM, Cure Genetics achieves a differentiated pipeline layout, leading the way in original innovation. By leveraging global collaborations and out-license, we actively drive the research & development, and commercialization of innovative drugs. We aim to provide effective treatment measures for patients worldwide with unmet medical needs and to become a benchmark in the global field of cell and gene therapy.
